SCHEMBL17144208

SCHEMBL17144208

COc1ccc(CCCN(CC(=O)N2CCCCC2)Cc2cc(C(=O)O)ccn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KDM5A P29375 1/20 0.40
▸ KDM4C Q9H3R0 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.39
▸ LPAR1 Q92633 2/20 0.39
▸ MEP1B Q16820 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ STS P08842 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16291875 0.84 KDM5C (0.43) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL16291490 0.82 HRH3 (0.45) KDM5AKDM4CKDM5BPROKR1
SCHEMBL15637391 0.80 KDM4C (0.44) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL19741729 0.78 KDM4C (0.41) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL16291657 0.78 DPP7 (0.42) KDM5AKDM4CKDM5BMEP1BNPC1
SCHEMBL15637002 0.77 KDM4C (0.41) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL17144856 0.74 KDM5C (0.44) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL19676391 0.73 KDM5C (0.41) HPGDKDM5AKDM4CKDM5BALDH1A1
SCHEMBL16291664 0.73 KDM4C (0.43) SMN1; SMN2HPGDKDM5AKDM4CKDM5B
SCHEMBL19676375 0.71 KDM4C (0.43) KDM5AKDM4CKDM5BPROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US claimed
EP-3126345-A1 INHIBITORS OF HISTONE DEMETHYLASES Gilead Sciences, Inc. (US) 2017-02-08 — — EP claimed
WO-2015153498-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS, APS (DK) 2015-10-08 — — WO claimed
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US disclosed
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES EPITHERAPEUTICS APS (DK) 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170369444-A1 INHIBITORS OF HISTONE DEMETHYLASES KDM1B, KDM3A, KDM1A SMN1; SMN2 2826/4885HPGD 717/4885KDM5A 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback